The crushing weight of student debt and the Great Recession have shaped millennials' relationship with money, for better or worse. In some, it has created enough anxiety about financial security that they save as much as they can and avoid any type of credit agreement that could cause them to take on more debt. Others become so preoccupied with their present expenses that they fail to save for the future.
Unfortunately, both approaches have their drawbacks. Here are a few of the most common money mistakes millennials are making -- and what you can do to fix them.
Image source: Getty Images.
1. Not preparing for the unexpectedAbout 46% of millennials don't have any money set aside in an emergency fund, according to a 2017 survey by GOBankingRates. This can pose a problem when an unexpected event like a home repair, a costly medical bill, or a sudden job loss puts an extra strain on your budget. Without any savings to cover these financial emergencies, you may have no choice but to take on debt or fall behind on your rent or mortgage payment and other bills, which can have a serious impact on your creditworthiness.
Top Medical Stocks To Watch For 2019: I.D. Systems, Inc.(IDSY)
Advisors' Opinion:- [By Logan Wallace]
I.D. Systems (NASDAQ: IDSY) and Lumentum (NASDAQ:LITE) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.
- [By Logan Wallace]
Get a free copy of the Zacks research report on I.D. Systems (IDSY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
Get I.D. Systems alerts: I.D. Systems, Inc. (IDSY) Expected to Announce Quarterly Sales of $12.32 Million (americanbankingnews.com) I.D. Systems, Inc. (IDSY) Expected to Announce Earnings of $0.01 Per Share (americanbankingnews.com) I.D. Systems integrates Keytroller, forms PowerFleet division (mmh.com) I.D. Systems Integrates Keytroller and Forms PowerFleet® Division Focused on Industrial Truck Management Systems (finance.yahoo.com)Several analysts have commented on IDSY shares. National Securities started coverage on shares of I.D. Systems in a research note on Monday, August 27th. They issued a “buy” rating and a $8.60 price target on the stock. ValuEngine upgraded shares of I.D. Systems from a “sell” rating to a “hold” rating in a research note on Thursday, June 7th. Finally, Zacks Investment Research downgraded shares of I.D. Systems from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $9.32.
- [By Shane Hupp]
TRADEMARK VIOLATION NOTICE: “I.D. Systems, Inc. (IDSY) Major Shareholder Purchases $381,042.60 in Stock” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4125843/i-d-systems-inc-idsy-major-shareholder-purchases-381042-60-in-stock.html.
- [By Shane Hupp]
xG Technology (NASDAQ: XGTI) and I.D. Systems (NASDAQ:IDSY) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Top Medical Stocks To Watch For 2019: Xcel Energy Inc.(XEL)
Advisors' Opinion:- [By Stephan Byrd]
Endesa (OTCMKTS: ELEZF) and Xcel Energy (NYSE:XEL) are both large-cap utilities companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
- [By Max Byerly]
Elastic (XEL) uses the hashing algorithm. It was first traded on June 8th, 2017. Elastic’s total supply is 100,000,000 coins and its circulating supply is 91,676,277 coins. The official website for Elastic is www.elastic.pw. Elastic’s official Twitter account is @elastic_coin. The Reddit community for Elastic is /r/XEL and the currency’s Github account can be viewed here. Elastic’s official message board is talk.elasticexplorer.org.
- [By Stephan Byrd]
Elastic (CURRENCY:XEL) traded down 6.9% against the U.S. dollar during the one day period ending at 0:00 AM ET on September 20th. One Elastic coin can now be purchased for $0.0548 or 0.00000836 BTC on popular cryptocurrency exchanges including Stellar Decentralized Exchange, Bittrex and Upbit. Elastic has a market cap of $5.02 million and approximately $37,867.00 worth of Elastic was traded on exchanges in the last 24 hours. During the last seven days, Elastic has traded 17.7% lower against the U.S. dollar.
Top Medical Stocks To Watch For 2019: Flexsteel Industries, Inc.(FLXS)
Advisors' Opinion:- [By Logan Wallace]
Flexsteel Industries, Inc. (NASDAQ:FLXS) hit a new 52-week low during trading on Monday . The stock traded as low as $30.57 and last traded at $30.38, with a volume of 1359 shares. The stock had previously closed at $31.53.
- [By Ethan Ryder]
Purple Innovation (NASDAQ: FLXS) and Flexsteel Industries (NASDAQ:FLXS) are both small-cap unclassified companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
- [By Shane Hupp]
BidaskClub cut shares of Flexsteel Industries (NASDAQ:FLXS) from a hold rating to a sell rating in a research report released on Friday morning.
Separately, ValuEngine lowered shares of Flexsteel Industries from a hold rating to a sell rating in a research report on Friday, April 27th.
- [By Logan Wallace]
Hooker Furniture (NASDAQ: HOFT) and Flexsteel Industries (NASDAQ:FLXS) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Top Medical Stocks To Watch For 2019: Galmed Pharmaceuticals Ltd.(GLMD)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Keith Speights]
That's exactly what happened this week with three small biotech stocks. Galmed Pharmaceuticals (NASDAQ:GLMD), Galectin Therapeutics (NASDAQ:GALT), and Eloxx Pharmaceuticals (NASDAQ:ELOX) soared on news that excited investors. Here's what drove these stocks higher -- and whether or not they're smart picks for investors now.
- [By Shane Hupp]
Here are some of the media stories that may have effected Accern’s rankings:
Get Galmed Pharmaceuticals alerts: Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltd's (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.
- [By Sean Williams]
Similar strength was seen from microcap Galmed Pharmaceuticals (NASDAQ:GLMD), which rose by more than 150% during a single trading session two weeks ago despite mixed results. The move followed the release of phase 2b data from its 52-week Arrest study for NASH drug hopeful Aramchol. In that trial, a statistically significant reduction in liver fat was noted with one of the two doses (the 400 mg dose). However, the 600 mg dose led to a statistically significant improvement in overall NASH resolution (19.2% vs. 7.5%) and NASH resolution without worsening of fibrosis (16.7% vs. 5%) relative to the placebo.
- [By Jon C. Ogg]
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) was started as Outperform with a $26 price target at Raymond James on July 20, and that was versus a previous $15.02 closing price. A week earlier, on June 13, Stifel Nicolaus initiated Galmed with a Buy rating and issued a $35 price target that would imply more than 100% upside. Galmed has been quite volatile as its 52-week range is listed at $3.61 to $27.06. It had a $322 million market cap as of Friday. Galmed, which focuses on diseases and issues targeting the liver, closed at $15.00 on Friday. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Medical Stocks To Watch For 2019: ON Semiconductor Corporation(ON)
Advisors' Opinion:- [By Joseph Griffin]
BidaskClub upgraded shares of ON Semiconductor (NASDAQ:ON) from a buy rating to a strong-buy rating in a research report report published on Wednesday morning.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ON Semiconductor (ON)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
ON Semiconductor Corp (NASDAQ:ON) has earned an average rating of “Buy” from the twenty-one analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $25.11.
No comments:
Post a Comment